|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
We have successfully used this method to analyze 60 leukemia samples (34 from Ph1-negative acute leukemias; 6 from Ph1-positive acute leukemias; and 20 from CML) with complete correlation (of BCR-ABL positivity or negativity) with the results of karyotype or Southern Blot analysis of genomic DNA for bcr rearrangement.
|
1985690 |
1991 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
BCR and BCR/ABL1 expression levels were analysed in CML cell lines after over-expression or silencing of MYC transcription factor.
|
26179066 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
In this study, we show in both BCR-ABL cells (Mo7e-p210 and BaF/3-p210) and primary CML CD34+ cells that STI571 inhibition of BCR-ABL tyrosine kinase activity results in a G(1) cell cycle arrest mediated by the PI3K pathway.
|
15833859 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Due to its inhibition of the Abl kinase domain in the BCR-ABL fusion protein, imatinib is strikingly effective in the initial stage of chronic myeloid leukemia with more than 90% of the patients showing complete remission.
|
26606374 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1 TKIs are effective therapies in CML but are associated with distinct safety profiles.
|
26637844 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The aberrant transcript presumably arose as a result of a lack of splicing, and chemotherapy might modify the disease course by selecting the subpopulation of the CML clone expressing typical BCR-ABL mRNA dominantly.
|
11378554 |
2001 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method.
|
21892537 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
BCR-ABL1 transcript quantification was performed in 117 samples from CML patients in two different laboratories by both methods, and the results were compared by statistical procedures.
|
22526369 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
In addition, PQ2 induced Bcr-Abl1 mediated ERK pathway in human chronic myelogenous leukemia (CML) cells.
|
31542717 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In chronic myeloid leukemia (CML) cells from different stages of maturation may have differential expression of BCR-ABL at both messenger RNA (mRNA) and protein level.
|
24269846 |
2014 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The typical triphasic course of CML starts with the premalignant chronic phase initiated by BCR-ABL hybrid oncogene formation.
|
11513567 |
2001 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2.
|
29411417 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
We have serially monitored peripheral blood and bone marrow BCR-ABL transcripts using qRT-PCR in CML patients commencing imatinib therapy, and compared the results with bone marrow cytogenetics.
|
15579919 |
2004 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
|
14744784 |
2004 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Chronic myelogenous leukemia (CML) is characterized by a balanced translocation that leads to the formation of the the BCR-ABL fusion gene.
|
10431169 |
1999 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In about 50% of the Ph-positive acute lymphoid leukemias (ALL), the bcr-abl gene fusion is identical to CML, while in 50% an alternative fusion between these two genes occurs, in which the central bcr-sequences are absent.
|
2407300 |
1990 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The p53 mutations and BCR/ABL mutation status analysis in CML patients were detected by PCR and direct sequencing.
|
26494558 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Chronic myeloid leukemia (CML) is associated to the BCR-ABL1 oncogene and can successfully be treated with tyrosine kinase inhibitors (TKIs).
|
27454607 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Oligonucleotide sets that probe breakpoints of <i>IGH-BCL2</i> (immunoglobulin heavy-apoptosis regulator) in follicular lymphoma (FL), <i>MYC-IGH</i> (MYC proto-oncogene, bHLH transcription factor-immunoglobulin heavy) in Burkitt lymphoma (BL) and <i>BCR-ABL1</i> (RhoGEF and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase) in chronic myelogenous leukemia (CML) were designed.
|
28515100 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center in China.
|
22349721 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A BCR/ABL transcript level at 6 months can identify a "good-risk" subgroup among patients who fail to achieve an EMR on Imatinib therapy for CML.
|
24619861 |
2014 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Through comparative analysis of different DNA double-strand break (DSB) repair mechanisms as a function of the BCR-ABL status in human megakaryocytic and CML cell lines, we found that BCR-ABL upregulates error-prone DSB repair pathways [single-strand annealing (SSA) and non-homologous end joining] rather than the high-fidelity mechanism of homologous recombination.
|
20974687 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
It is important to understand how various genes that are involved in regulating the signaling pathway and epigenetic deregulation cooperate with the BCR/ABL1 fusion in the initiation and progression of CML.
|
22118744 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
For such cases about CML with variant Philadelphia chromosome translocations or BCR-ABL kinase region mutation, TKI may still be valuable.
|
30335005 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We describe two patients with CML and normal karyotype in whom cryptic rearrangements involving chromosomes 9 and 22 resulted in the causative BCR/ABL gene.
|
16337861 |
2005 |